Impact of the p53 status of tumor cells on extrinsic and intrinsic apoptosis signaling

Cell Communication and Signaling

Volumn 11, Issue 1, 2013, Pages

  Wachter, Franziska ^a   Grunert, Michaela ^a   Blaj, Cristina ^a   Weinstock, David M ^b   Jeremias, Irmela ^a,c   Ehrhardt, Harald ^a,c  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Apoptosis; Doxorubicin; Extrinsic; Intrinsic; Mutant p53; p53; TRAIL

Indexed keywords

PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL MUTANT; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; P53 GENE; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR XENOGRAFT; WILD TYPE;

EID: 84877031772     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/1478-811X-11-27     Document Type: Article

References (39)

1. Massively regulated genes: the example of TP53. Hollstein M, Hainaut P, J Pathol 2010 220 164 173 19918835
2. Optimized anti-tumor effects of anthracyclines plus vinca alkaloids using a novel, mechanism-based application schedule. Ehrhardt H, Schrembs D, Moritz C, Wachter F, Haldar S, Graubner U, Nathrath M, Jeremias I, Blood 2011 118 6123 6131 10.1182/blood-2010-02-269811 21926351
3. Important role of Caspase-8 for chemo-sensitivity of ALL cells. Ehrhardt H, Wachter F, Maurer M, Stahnke K, Jeremias I, Clin Cancer Res 2011 17 7605 7613 10.1158/1078-0432.CCR-11-0513 22010212
4. NOXA as critical mediator for drug combinations in polychemotherapy. Ehrhardt H, Höfig I, Obexer P, Fulda S, Terziyska N, Jeremias I, Cell Death Dis 2012 3 327 10.1038/cddis.2012.53
5. DNA binding cooperativity of p53 modulates the decision between cell-cycle arrest and apoptosis. Schlereth K, Beinoraviciute-Keller R, Zeitlinger MK, Bretz AC, Sauer M, Charles JP, Vogiatzi F, Leich E, Samans B, Eilers M, Kisker C, Rosenwald A, Stiewe T, Mol Cell 2010 38 356 368 10.1016/j.molcel.2010.02.037 20471942
6. Life or death: p53-induced apoptosis requires DNA binding cooperativity. Schlereth K, Charles JP, Bretz AC, Stiewe T, Cell Cycle 2010 9 4068 4076 10.4161/cc.9.20.13595 20948308
7. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Peller S, Rotter V, Hum Mutat 2003 21 277 284 10.1002/humu.10190 12619113
8. The p53 pathway as a target in cancer therapeutics: obstacles and promise. Mandinova A, Lee SW, Sci Transl Med 2011 3 64rv1 10.1126/scitranslmed. 3001366 21209413
9. Translating p53 into the clinic. Cheok CF, Verma CS, Baselga J, Lane DP, Nat Rev Clin Oncol 2011 8 25 37 10.1038/nrclinonc.2010.174 20975744
10. Specific p53 mutants are associated with de novo resistance to doxorubicin in breast cancer patients. Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA, Lønning PE, Nat Med 1996 2 811 814 10.1038/nm0796-811 8673929
11. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Casey G, Lo-Hsueh M, Lopez ME, Vogelstein B, Stanbridge EJ, Oncogene 1991 6 1791 1799 1923504
12. Oncogenic forms of p53 inhibit p53-regulated gene expression. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B, Science 1992 256 827 830 10.1126/science.1589764 1589764
13. p53 downstream target genes and tumor suppression: a classical view in evolution. Rozan LM, El-Deiry WS, Cell Death Differ 2007 14 3 9 10.1038/sj.cdd.4402058 17068503
14. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T, Cell 2004 119 847 860 10.1016/j.cell.2004.11.004 15607980
15. High metastatic potential in mice inheriting a targeted p53 missense mutation. Liu G, McDonnell TJ, Montes de Oca, Luna R, Kapoor M, Mims B, El-Naggar AK, Lozano, Proc Natl Acad Sci USA 2000 97 4174 4179 10.1073/pnas.97.8.4174 10760284
16. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M, Hum Mutat 2007 28 622 629 10.1002/humu.20495 17311302
17. The dark side of a tumor suppressor: anti-apoptotic p53. Jänicke RU, Sohn D, Schulze-Osthoff K, Cell Death Differ 2008 15 959 976 10.1038/cdd.2008.33 18356920
18. p53: an ubiquitous target of anticancer drugs. Blagosklonny MV, Int J Cancer 2002 98 161 166 10.1002/ijc.10158 11857402
19. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Wada M, Bartram CR, Nakamura H, Hachiya M, Chen DL, Borenstein J, Miller CW, Ludwig L, Hansen-Hagge TE, Ludwig WD, Reiter A, Mizoguchi H, Koeffler HP, Blood 1993 82 3163 3169 8219205
20. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE, Vora A, Mitchell CD, Harrison CJ, Lancet Oncol 2010 11 429 438 10.1016/S1470-2045(10)70066-8 20409752
21. Efficient RNA interference in patients'acute lymphoblastic leukemia cellsamplified as xenografts in mice. Höfig I, Ehrhardt H, Jeremias I, Cell Commun Signal 2012 10 8 10.1186/1478-811X-10-8 22448764
22. Humanized mice in translational biomedical research. Shultz LD, Ishikawa F, Greiner DL, Nat Rev Immunol 2007 7 118 130 10.1038/nri2017 17259968
23. Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI). Sandberg R, Ernberg I, Proc Natl Acad Sci USA 2005 102 2052 2057 10.1073/pnas.0408105102 15671165
24. Cancer cell lines as genetic models of their parent histology: analyses based on array comparative genomic hybridization. Greshock J, Nathanson K, Martin AM, Zhang L, Coukos G, Weber BL, Zaks TZ, Cancer Res 2007 67 3594 3600 10.1158/0008-5472.CAN-06-3674 17440070
25. p53 suppresses the activation of the Bcl-2 promoter by the Brn-3a POU family transcription factor. Budhram-Mahadeo V, Morris PJ, Smith MD, Midgley CA, Boxer LM, Latchman DS, J Biol Chem 1999 274 15237 15244 10.1074/jbc.274.21. 15237 10329733
26. Repression of glucocorticoid receptor transactivation and DNA binding of a glucocorticoid response element within the serum/glucocorticoid-inducible protein kinase (sgk) gene promoter by the p53 tumor suppressor protein. Maiyar AC, Phu PT, Huang AJ, Firestone GL, Mol Endocrinol 1997 11 312 329 10.1210/me.11.3.312 9058378
27. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Kanaya T, Kyo S, Hamada K, Takakura M, Kitaqawa Y, Harada H, Inoue M, Clin Cancer Res 2000 6 1239 1247 10778946
28. p53 represses c-Myc through induction of the tumor suppressor miR-145. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, Mo YY, Proc Natl Acad Sci USA 2009 106 3207 3212 10.1073/pnas.0808042106 19202062
29. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Chipuk JE, Maurer U, Green DR, Schuler M, Cancer Cell 2003 4 371 381 10.1016/S1535-6108(03)00272-1 14667504
30. Modulating the p53 pathway. Dey A, Lane DP, Verma CS, Semin Cancer Biol 2010 20 3 9 10.1016/j.semcancer.2010.02.004 20193765
31. A large intergentic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, Khalil AM, Zuk O, Amit I, Rabani M, Attardi LD, Regev A, Lander ES, Jacks T, Rinn JL, Cell 2010 142 409 419 10.1016/j.cell.2010.06.040 20673990
32. The role of mutant p53 in human cancer. Goh AM, Coffill CR, Lane DP, J Pathol 2011 223 116 126 10.1002/path.2784 21125670
33. TRAIL-mediated proliferation of tumor cells with receptor-close apoptosis defects. Baader E, Toloczko A, Fuchs U, Schmid I, Beltinger C, Ehrhardt H, Debatin KM, Jeremias I, Cancer Res 2005 65 7888 7895 16140959
34. New insights into apoptosis signalling by Apo2L/TRAIL. Gonzalves F, Ashkenazi A, Oncogene 2010 29 4752 4765 10.1038/onc.2010.221 20531300
35. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, Kenzelmann Broz D, Basak S, Park EJ, McLaughlin ME, Karnezis AN, Attardi LD, Cell 2011 145 571 583 10.1016/j.cell.2011.03.035 21565614
36. The adaptor protein FADD and the initiator caspase-8 mediate activation of NFκB by TRAIL. Grunert M, Gottschalk K, Kapahnke J, Gündisch S, Kieser A, Jeremias I, Cell Death Disease 2012 3 414 10.1038/cddis.2012.154 23096115
37. Enhanced antitumor effects of vinca alkaloids given separately from cytostatic therapies. Ehrhardt H, Pannert L, Pfeiffer S, Wachter F, Amtmann E, Jeremias I, Br J Pharmacol 2013 168 1558 1569 10.1111/bph.12068 23186127
38. Cytotoxic drug-induced, p53-mediated upregulation of Caspase-8 in tumor cells. Ehrhardt H, Haecker S, Wittmann S, Maurer M, Borkhardt A, Toloczko A, Debatin KM, Fulda S, Jeremias I, Oncogene 2008 27 783 793 10.1038/sj.onc.1210666 17637740
39. Next-generation cDNA screening for oncogene and resistance phenotype. Shindoh N, Yoda A, Sullivan TJ, Weigert O, Lane AA, Kopp N, Bird L, Rodig SJ, Fox EA, Weinstock DM, PLoS One 2012 7 49201 10.1371/journal.pone.0049201 23145123